Literature DB >> 9139239

Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos.

V C Hinz1, S Grewig, B H Schmidt.   

Abstract

Metrifonate, a long-acting cholinesterase (ChE) inhibitor with very low toxicity in warm-blooded animals, inhibits rat brain and serum cholinesterase (ChE) in vitro through its hydrolytic degradation product, dichlorvos. This conclusion is based on the finding that metrifonate-induced ChE inhibition showed the same pH dependence as its reported dehydrochlorination to dichlorvos. The ChE inhibition induced by dichlorvos was not pH dependent. It was mediated by a competitive drug interaction with the catalytic site of the enzyme, which led to irreversible inhibition within several minutes of incubation. After this time, addition of further substrate to the inhibited enzyme was not able to promote drug dissociation and hence enzyme reactivation. Similar characteristics of inhibition, i.e. interaction with the substrate binding site and time-dependent switch to non-competitive inhibition were observed with the reference compound, physostigmine. However, the physostigmine-induced inhibition of ChE could be readily reversed by further substrate addition. Another reference compound, tetrahydroaminoacridine (THA), also induced a reversible inhibition of rat brain and serum cholinesterase, but with a mechanism of action different from that of both dichlorvos and physostigmine in that enzyme inhibition occurred rapidly upon drug addition at an allosteric site on the enzyme surface. It is suggested that the unique slow release plus the slow inhibition of ChE by dichlorvos is responsible for the lower toxicity of metrifonate compared to that of directly acting ChE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9139239     DOI: 10.1007/bf02531649

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

Review 1.  The cholinergic system in Alzheimer disease.

Authors:  E Giacobini
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

Review 2.  Cholinergic receptors in human brain: effects of aging and Alzheimer disease.

Authors:  E Giacobini
Journal:  J Neurosci Res       Date:  1990-12       Impact factor: 4.164

3.  Tacrine protection of acetylcholinesterase from inactivation by diisopropylfluorophosphate: a circular dichroism study.

Authors:  C S Wu; J T Yang
Journal:  Mol Pharmacol       Date:  1989-01       Impact factor: 4.436

Review 4.  Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease.

Authors:  E Giacobini
Journal:  Keio J Med       Date:  1987-10

5.  Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry.

Authors:  T Villén; Y A Abdi; O Ericsson; L L Gustafsson; F Sjöqvist
Journal:  J Chromatogr       Date:  1990-08-03

Review 6.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

Review 7.  Acetylcholine and memory.

Authors:  M E Hasselmo; J M Bower
Journal:  Trends Neurosci       Date:  1993-06       Impact factor: 13.837

8.  Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

Authors:  L M Bierer; V Haroutunian; S Gabriel; P J Knott; L S Carlin; D P Purohit; D P Perl; J Schmeidler; P Kanof; K L Davis
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

Review 9.  Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.

Authors:  V Kumar; R E Becker
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-10

10.  Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.

Authors:  S A Beller; J E Overall; A C Swann
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  6 in total

1.  Metrifonate and dichlorvos: effects of a single oral administration on cholinesterase activity in rat brain and blood.

Authors:  V Hinz; S Grewig; B H Schmidt
Journal:  Neurochem Res       Date:  1996-03       Impact factor: 3.996

Review 2.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Metrifonate.

Authors:  H M Lamb; D Faulds
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 4.  Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

Authors:  B P Imbimbo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Effects of subchronic administration of metrifonate on cholinergic neurotransmission in rats.

Authors:  V C Hinz; J Kolb; B H Schmidt
Journal:  Neurochem Res       Date:  1998-07       Impact factor: 3.996

6.  In Vivo Sub-chronic Treatment with Dichlorvos in Young Rats Promotes Synaptic Plasticity and Learning by a Mechanism that Involves Acylpeptide Hydrolase Instead of Acetylcholinesterase Inhibition. Correlation with Endogenous β-Amyloid Levels.

Authors:  Gonzalo García-Rojo; Fernando Gámiz; Estíbaliz Ampuero; Daniel Rojas-Espina; Rodrigo Sandoval; Carlos Rozas; Bernardo Morales; Ursula Wyneken; Floria Pancetti
Journal:  Front Pharmacol       Date:  2017-07-25       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.